Skip to content
Save up to 80% Fast & Discrete Delivery
Femara
Quality products
Fast & Discrete Delivery
Money-back guarantee

Femara

4.3 (4 customer reviews)
Delivery: from 4 days
Payment
24/7 Support
Active ingredient: Letrozole

Free delivery on orders from AED 860.00, free express delivery from AED 1,290.00

256-bit SSL
Certified pharmacy
Money-back guarantee

Femara is used mainly for hormone receptor-positive breast cancer in postmenopausal women and may also support ovulation induction in selected fertility plans. Its key benefit is lowering oestrogen production, which can reduce tumour stimulation and support ovulation in specific clinical settings.

Product information

Letrozole, the active ingredient of Femara, is a non-steroidal aromatase inhibitor supplied as oral tablets. It is used mainly for hormone receptor-positive breast cancer in postmenopausal women and may also be prescribed for ovulation induction in selected fertility plans. By lowering oestrogen production, Femara slows oestrogen-dependent tumour stimulation and can support ovulation in specific clinical settings.

Ingredients

Femara contains letrozole. Letrozole belongs to the aromatase inhibitor class, which reduces the body’s production of oestrogen rather than blocking oestrogen receptors directly.

Aromatase is an enzyme found in fatty tissue, muscle, and breast tissue. After menopause, it becomes a major source of circulating oestrogen. Femara reduces aromatase activity, helping lower oestradiol levels in people whose cancer cells depend on oestrogen signalling for growth. [1]

Therapeutic indications

Femara is prescribed for hormone receptor-positive breast cancer in postmenopausal women. It may be used after surgery, following tamoxifen therapy, or for advanced breast cancer, depending on the tumour stage and the treatment plan.

Its main oncology uses include:

  • Adjuvant treatment of early hormone receptor-positive breast cancer.
  • Extended adjuvant treatment after previous tamoxifen therapy.
  • Treatment of locally advanced or metastatic hormone receptor-positive breast cancer.
  • First-line endocrine treatment for postmenopausal women with advanced disease.

Letrozole is also used off-label as a fertility drug for ovulation induction, especially in women with anovulatory infertility related to polycystic ovary syndrome. The American Society for Reproductive Medicine recognises letrozole as a first-line pharmacological option for ovulation induction in many women with PCOS who are not ovulating regularly. [2]

The two uses require different clinical planning. Breast cancer treatment aims for sustained oestrogen reduction, while fertility protocols use a short, cycle-specific course to encourage follicle development. Oncology regimens are reviewed against tumour characteristics and treatment response. Fertility cycles are monitored for follicle development and ovulation. A clinician should select the regimen and monitoring plan for the indication.

Dosage and administration

Femara tablets are swallowed whole with water. The tablet should not be crushed unless a prescriber has given a specific reason to do so.

For fertility use, timing is part of the treatment plan. Starting tablets on the wrong cycle day can change the intended hormonal response, so the prescribed schedule should be followed exactly.

Femara is supplied as tablets for oral use. Dosing differs between strengths and between users, so there is no single amount that suits everyone.

For breast cancer, the prescribed amount and schedule depend on the individual treatment plan and may continue for an extended period when used as adjuvant endocrine therapy, depending on recurrence risk, prior treatment, bone health, and tolerability.

For ovulation induction, the dose and number of treatment days are set by the fertility specialist for a specific menstrual cycle. It is not used as a continuous daily fertility treatment.

  • Swallow the tablet with water.
  • Take it at a consistent time each day for oncology treatment.
  • It may be taken with or without food.
  • If a dose is missed, take it when remembered unless the next dose is due soon.
  • Do not take two tablets together to make up for a forgotten dose.
Choose a time that fits an existing routine, such as after brushing teeth in the morning. The best time is the one least likely to be missed, provided it remains consistent.

A missed tablet is usually less concerning than repeated missed doses. Keeping a simple medication record can help during long endocrine treatment courses.

When not to use it

Femara is not for you if you are pregnant, breastfeeding, have a known allergy to letrozole or tablet ingredients, or have not reached menopause when it is being considered for breast cancer treatment.

Extra caution is needed with:

  • Significant liver impairment, because letrozole is metabolised in the liver.
  • Osteoporosis, previous fragility fractures, or major bone-density loss.
  • High cholesterol or established cardiovascular risk.
  • Medicines that affect oestrogen pathways.
  • Tamoxifen, which may reduce letrozole blood concentrations when used together.

Oestrogen-containing medicines can counteract the intended oestrogen-lowering effect of letrozole. This includes hormone replacement therapy and some hormonal contraceptive approaches.

When this is not for you

Letrozole can harm a developing fetus. Women using Femara for fertility need a documented plan for excluding pregnancy before each treatment cycle where clinically appropriate. It should not be continued once pregnancy is confirmed.

Possible side effects

Hot flushes, joint pain, fatigue, sweating, headache, dizziness, nausea, and muscle discomfort are among the more common effects of Femara. Low oestrogen is the reason for many of these symptoms.

Longer treatment can reduce bone mineral density and raise the risk of osteoporosis and fractures. Letrozole may also increase cholesterol levels. Regular assessment of bone health and cardiovascular risk is often part of longer oncology treatment. [4]

Seek urgent medical assessment for:

  • Sudden chest pain, shortness of breath, or coughing blood.
  • New one-sided leg swelling or pain.
  • Facial swelling, severe rash, wheezing, or difficulty breathing.
  • Severe weakness, fainting, confusion, or new neurological symptoms.
  • Yellowing of the eyes or skin, dark urine, or persistent upper abdominal pain.
Do not dismiss a new limp as ordinary ageing during long-term treatment. Persistent hip, back, or groin pain can warrant bone assessment, especially when it appears after a fall or becomes worse at night.

How it affects the body

Letrozole inhibits aromatase, also called CYP19. This enzyme converts androgens into oestrogens, including estradiol.

When Femara lowers oestrogen levels in postmenopausal breast cancer, it reduces stimulation of hormone-sensitive tumour cells. The effect is systemic, so low oestrogen can also affect bone, joints, vaginal tissue, and blood lipid levels.

In fertility treatment, a temporary reduction in oestrogen changes feedback signalling between the ovaries and brain. The pituitary gland may release more follicle-stimulating hormone, or FSH, which can support follicle recruitment and ovulation.

Aromatase inhibition differs from selective oestrogen receptor modulators. Letrozole reduces oestrogen synthesis; receptor modulators act by blocking or modifying oestrogen activity in certain tissues. This difference explains why their adverse-effect patterns and treatment roles are not identical. [3]

Common mistakes

  • Stopping daily oncology treatment after a few weeks because hot flushes or stiffness begin.
  • Taking an extra tablet after forgetting one.
  • Combining Femara with oestrogen therapy without discussing the interaction.
  • Ignoring new bone pain or repeated falls during long-term treatment.
  • Using a breast cancer dosing routine for fertility purposes.
  • Assuming that absence of symptoms means the treatment is not working.

A common fertility mistake is treating ovulation induction as a general hormone supplement. Letrozole is prescribed for specific cycle days, and changing the schedule without guidance can disrupt monitoring and ovulation timing.

If joint symptoms begin after starting Femara, record where the pain occurs, its morning severity, and whether movement helps. This gives the prescriber much more useful information than simply reporting aches.

Comparison

Femara is an aromatase inhibitor. Tamoxifen and clomiphene are selective oestrogen receptor modulators, while gonadotropins directly stimulate the ovaries through injectable hormones.

Treatment approach Main mechanism Typical clinical role
Letrozole Inhibits aromatase and lowers oestrogen synthesis Postmenopausal hormone-sensitive breast cancer; ovulation induction
Tamoxifen Modifies oestrogen receptor activity in different tissues Breast cancer treatment and prevention in selected patients
Clomiphene Blocks oestrogen feedback at the hypothalamus Ovulation induction

For postmenopausal breast cancer, letrozole is often selected because reducing oestrogen production can provide strong endocrine control. Tamoxifen remains valuable in several settings, including many premenopausal treatment plans.

For fertility, letrozole may be favoured in women with PCOS because it usually has less persistent anti-oestrogen activity on cervical mucus and the endometrium than clomiphene. Gonadotropins can be considered when oral ovulation induction is unsuccessful, though they require closer monitoring and carry a higher risk of multiple follicle development.

What doctors say

In oncology practice, clinicians often explain that Femara is a long-term risk-reduction treatment rather than a tablet expected to produce a noticeable daily benefit. The goal is to reduce oestrogen stimulation of hormone-sensitive cancer cells and lower the chance of recurrence over time.

Doctors also watch for the trade-off between cancer control and low-oestrogen effects. Joint pain, vaginal dryness, sleep disruption, reduced bone density, and lipid changes deserve active management rather than silent endurance.

For fertility treatment, clinicians use letrozole as a targeted, short-course medicine. Ovulation may occur, yet pregnancy is never guaranteed in a single cycle because sperm factors, tubal patency, egg quality, timing, and uterine factors still matter.

Comparison

Arimidex

Active ingredient: Anastrozole
1mg
From AED 834.20
pills
3.9 (5)

Femara Current

Active ingredient: Letrozole
2.5mg
From AED 412.80
pills
4.3 (4)

Hydrea

Active ingredient: Hydroxycarbamide
500mg
From AED 485.90
pills
3.8 (5)

Comparison table: Oncology

Common questions

Can Femara be used if I am pregnant?

No. Pregnancy rules out Femara use because letrozole can cause fetal harm. Pregnancy status is especially relevant when Femara is prescribed for ovulation induction, since treatment is designed to occur before conception rather than during pregnancy. The 2023 WHO Model Formulary lists aromatase inhibitors among medicines requiring strict pregnancy precautions due to their hormonal effects. [5]

Can I drink alcohol while using Femara?

Alcohol does not have a major direct pharmacological interaction with letrozole, yet it can worsen dizziness, fatigue, poor sleep, and flushing. Regular alcohol intake can also affect bone health and liver function, which matters during longer endocrine therapy. The 2023 EMA product information advises attention to effects such as dizziness and fatigue when taking letrozole. If alcohol makes symptoms more noticeable, reducing or avoiding it is sensible.

Which symptoms mean I should stop Femara and seek urgent medical care?

Stop taking Femara and seek urgent medical care for signs of a serious allergic reaction, such as facial swelling, wheezing, widespread blistering rash, or trouble breathing. Urgent assessment is also needed for sudden chest pain, shortness of breath, coughing blood, or one-sided leg swelling because these symptoms can indicate a serious vascular event. The 2023 FDA prescribing information identifies serious adverse reactions that require prompt clinical evaluation. Do not restart treatment until a clinician has assessed the cause.

What is the best time of day to take Femara?

For breast cancer treatment, Femara can be taken at a time that supports consistent daily use. Morning suits some people because it is easier to remember, while evening may suit those who experience daytime fatigue or dizziness. Letrozole may be taken with or without food, according to the 2023 EMA product information. The key point is maintaining a similar daily schedule rather than chasing a supposedly perfect hour.

Can Femara be combined with tamoxifen or oestrogen-containing supplements?

Femara should not be combined with tamoxifen unless the oncology team has intentionally planned a treatment sequence. Tamoxifen can lower letrozole concentrations, while oestrogen-containing medicines may oppose the intended oestrogen-lowering action. This includes hormone replacement therapy and supplements marketed for menopausal symptoms that contain hormonal ingredients. The 2023 FDA prescribing information documents this interaction in Femara prescribing information.

Does Femara cause joint pain?

Yes. Joint pain, stiffness, and muscle discomfort are well-recognised effects of letrozole because oestrogen contributes to joint and connective-tissue function. Symptoms may begin gradually and can be most noticeable after rest or on waking. A 2019 ASCO guideline on adjuvant endocrine therapy highlights musculoskeletal symptoms and bone health as practical issues during aromatase inhibitor treatment. Persistent pain should be assessed, since exercise support, pain management, bone evaluation, or a treatment adjustment may help.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Sources

  1. European Medicines Agency (2023). Summary of Product Characteristics (SmPC) — letrozole
  2. American Society for Reproductive Medicine (2023). Evidence-based treatments for couples with infertility: a committee opinion
  3. National Cancer Institute (2024). Hormone Therapy for Breast Cancer Fact Sheet
  4. U.S. Food and Drug Administration (2023). Femara (letrozole) prescribing information
  5. World Health Organization (2023). WHO Model Formulary 2023

Reviews: Femara

Hina, 46
Al Barsha
Five months
Verified
Rating: 4 out of 5
I took Femara after completing my main treatment. Building it into my breakfast routine helped me stay consistent, and I felt reassured that I was continuing with the hormonal part of my care.
17 Oct 2026
Mona, 55
Jumeirah
Eight months
Verified
Rating: 5 out of 5
I used Femara every morning before work. The daily routine became easy, and I was satisfied to have a clear long-term plan after surgery.
26 Oct 2026
Huda V., 39
Kalba
Two monitored cycles
Verified
Rating: 3.5 out of 5
I used Femara during two monitored cycles. The first cycle was slow and I had a few headaches, but the second cycle showed a better follicle response. The timing appointments were the inconvenient part.
31 Oct 2026
Ayesha, 29
Jebel Ali
Cycle-based tablets
Verified
Rating: 4.5 out of 5
I took Femara as part of a planned ovulation cycle. The instructions were straightforward, and I appreciated having a treatment that fitted into my routine without injections.
13 Nov 2026
Get our free app Shop faster and track your orders 3.9 · 268 reviews Install